Acromegaly
Conditions
Keywords
Acromegaly, Octreotide, IGF-1, Growth Hormone, Implant, Hydrogel
Brief summary
This is a long term study to evaluate the safety, tolerability and efficacy of an Octreotide Implant in patients that were previously treated with an Octreotide implant.
Detailed description
Evaluation on the long-term safety and tolerability, including local tolerability of the implant site, of the 84-mg octreotide hydrogel implant in subjects with acromegaly who had been successfully treated with the 84-mg octreotide hydrogel implant in the Phase III study IP107-001.
Interventions
DRUGOctreotide
84 mg Octreotide Implant
Sponsors
Endo Pharmaceuticals
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Currently enrolled in the Extension Phase of Study IP107-001 and received at least one 84-mg octreotide hydrogel implant prior to enrollment OR previously enrolled in the Extension Phase of Study IP107-001 and currently taking lanreotide or octreotide. * Subjects who have been successfully treated with the 84-mg octreotide hydrogel implant in Study IP107 001. * In the opinion of the Investigator; subject has no unstable chronic medical conditions and no clinically significant findings that would preclude subject's participation in the study. * Subjects must be able to communicate, provide and sign written informed consent, and be willing to participate and comply with study requirements.
Exclusion criteria
* Pituitary surgery less than 3 months prior to enrollment into this study * Liver disease (eg, cirrhosis, chronic active or persistent hepatitis or persistent abnormalities of ALT, AST \[level \>2× normal\] or direct bilirubin \[level \>1.5× normal\]) * Unstable angina, sustained ventricular arrhythmias or heart failure (NYHA III and IV) * Acute myocardial infarction within 3 months of Screening * Uncontrolled diabetes defined as having an HbA1c ≥9% * Symptomatic cholelithiasis * History of drug or alcohol abuse * Received any investigational drug or participated in another clinical trial except for study IP107 001 within 30 days of enrollment into this study * Received radiotherapy for pituitary tumor or any radiotherapy above the neck at any time prior to enrollment into this study * Receiving pegvisomant, dopamine agonist or other therapy in combination with somatostatin to control GH or IGF-1 levels prior to enrollment into this study * History or presence of significant cardiovascular, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, psychiatric disease, any other severe coexisting or, terminal systemic disease that limits life expectancy, or may interfere with the conduct of the study, or subjects who are incarcerated in penal institutions or are committed to mental institutions * Women who are pregnant or lactating. For females of childbearing potential, a positive pregnancy test prior to enrollment, or an unwillingness to use accepted forms of reliable birth control for study duration (including bilateral tubal ligation, use of oral contraceptives, double barrier methods \[diaphragm with spermicidal gel or condoms with contraceptive foam\], Depo-Provera®, hormonal implants, partner vasectomy, and total abstinence). Pregnancy tests are not required (indicate n/a) for males, or for females not of childbearing potential (post-menopausal with last menstrual period \>1 year ago or total hysterectomy with bilateral oophorectomy) * An unwillingness on the part of a male subject to abstain from sexual intercourse with pregnant or lactating women or an unwillingness to use a condom and spermicide and another form of contraception (eg, IUD, birth control pills taken by female partner, diaphragm with spermicide) if engaging in sexual intercourse with a woman who could become pregnant until discharge from the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Long term safety and tolerability of the Octreotide Implant | every 3 months for up to 2 years | Subjects will be assessed every 3 months via adverse event reporting and examination of the implantation site |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Evaluate the long term efficacy of the Octreotide Implant | every 3 months for up to 2 years | Patients will have GH and IGF-1 analyzed every 3 months |
Countries
United States
Outcome results
None listed